Optiver Holding’s Atossa Therapeutics ATOS Stock Holding History

Optiver Holding’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56	Closed	-$494	–	2332
2025 Q4	$494	Buy	+56	New	+$708	﹤0.01%	2296

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Optiver Holding's ATOS Position: Q1 2026 in Review

Optiver Holding sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 56 shares — an estimated $494 sold.

Optiver Holding first reported a position in ATOS in Q4 2025 and held it in 1 quarter. The position peaked at $494 in Q4 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Optiver Holding reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Optiver Holding sold 56 Atossa Therapeutics shares in Q1 2026, an estimated $494.
Optiver Holding first reported a position in Atossa Therapeutics in Q4 2025 and held it in 1 quarter.
Optiver Holding's Atossa Therapeutics position peaked at $494 in Q4 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.